Navigation Links
YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
Date:11/11/2010

multiforme.

Other highlights:

  • YM announced that Pulmokine Inc. (Slingerlands, New York), a licensee of several small molecule compounds from YM, has been awarded two National Institutes of Health (NIH) Small Business Innovation Research (SBIR) grants. The grants, totaling more than US$650,000, are Phase I awards to develop novel treatments for Pulmonary Arterial Hypertension (PAH).

  • Subsequent to quarter end, Dr. Nick Glover will be appointed as Chief Executive Officer of the Company to be effective at the Company's Annual General Meeting on November 18, 2010. Dr. Glover is also nominated to stand for election as a Director of the Company at that time. Mr. David Allan, who has been Chairman of the Company since its founding in 1994 and CEO since 1998, will continue to serve as Chairman of YM's Board of Directors.

  • Subsequent to quarter end, Dr. Mark Kowalski joined YM BioSciences as Chief Medical Officer and Vice President, Regulatory Affairs. Dr. Kowalski was formerly the Chief Medical Officer and Vice President, Regulatory Affairs at Viventia Biotechnology Inc., a biopharmaceutical company involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer. Prior to joining Viventia, Dr. Kowalski was the Director, and then Senior Director of Medical Affairs at AAIPharma Inc. Dr. Kowalski holds a B.A. from Rutgers University, and a M.D. and Ph.D. from the University of Kansas School of Medicine. He completed his postgraduate training in Internal Medicine and Infectious Diseases at Duke University and Harvard Medical School.
  • Financial Results (CDN dollars) Total revenue for the first quarter of fiscal 2011, ended September 30, 2010, was $0.4 million compared to $0.7 million for the first quarter of fiscal 2010, ended September 30, 2009. Revenue from licensees was $0.3 million for first quarter of fiscal 2011 compared to $0.7 million for the f
    '/>"/>

    SOURCE YM BioSciences Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
    2. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
    3. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
    4. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    5. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
    6. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    7. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
    8. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500â„¢
    9. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
    10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
    11. Cell Biosciences to Acquire Convergent Bioscience
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... 2014 Physicians Choice Laboratory Services ... menu, which enables healthcare providers to individualize therapeutic ... evidence-based results, healthcare providers are better able to ... while minimizing risks for adverse drug reactions and ... the FDA [1] more than 2.2 million adverse ...
    (Date:10/22/2014)... Nuvilex, Inc. (OTCQB: NVLX) – According to ... are living with diabetes, with  that number expected to ... market for diabetes treatments is approximately $500 billion.  ... from pancreatic cancer.  Pancreatic cancer is the fourth most ... the United States , and according to ...
    (Date:10/20/2014)... 20, 2014 Mapp Biopharmaceutical,s valiant effort ... therapeutic to fight the Ebola outbreak will make ... the production of pharmaceuticals can be, according to ... that while some may be taken aback by ... with industry knowledge are well aware of the ...
    (Date:10/20/2014)... , A major pan-European survey ... delivery of care has revealed changing trends in many ... the provision of healthcare services across the continent. The ... European Gastroenterology (UEG), have been announced today and led ... the burden of GI disorders across Europe ...
    Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
    ... Avantium announced today the,successful completion of a ... active in the development and commercialization of ... the improvement of,pharmaceutical products. The financing will ... programs. The focus of the next-generation biofuel,and ...
    ... 29 The Fondation du Centre hospitalier,universitaire de ... has donated a Waters(R) Synapt(TM) MS System, the ... a total C$1.1 million,-- is the result of ... critical,to the creation of the Centre d,expertise en ...
    ... Nasdaq: SHPGY) the global specialty biopharmaceutical,company announces results for the three ... - Product sales up 31% to $713 million - ... - New product sales(1) $276 million, 39% of product sales (2007: ... $779 million - Non GAAP earnings(2) per ADS up 88% ...
    Cached Biology Technology:Avantium Completes EUR 18 Million Financing Round 2Avantium Completes EUR 18 Million Financing Round 3Avantium Completes EUR 18 Million Financing Round 4Waters Corporation Gives Boost to Clinical Research Programs at University of Sherbrooke Hospital 2Waters Corporation Gives Boost to Clinical Research Programs at University of Sherbrooke Hospital 3Waters Corporation Gives Boost to Clinical Research Programs at University of Sherbrooke Hospital 4Waters Corporation Gives Boost to Clinical Research Programs at University of Sherbrooke Hospital 5Shire's New Product Portfolio Delivers Strong Quarterly Performance 2Shire's New Product Portfolio Delivers Strong Quarterly Performance 3Shire's New Product Portfolio Delivers Strong Quarterly Performance 4Shire's New Product Portfolio Delivers Strong Quarterly Performance 5Shire's New Product Portfolio Delivers Strong Quarterly Performance 6Shire's New Product Portfolio Delivers Strong Quarterly Performance 7Shire's New Product Portfolio Delivers Strong Quarterly Performance 8Shire's New Product Portfolio Delivers Strong Quarterly Performance 9Shire's New Product Portfolio Delivers Strong Quarterly Performance 10Shire's New Product Portfolio Delivers Strong Quarterly Performance 11Shire's New Product Portfolio Delivers Strong Quarterly Performance 12Shire's New Product Portfolio Delivers Strong Quarterly Performance 13Shire's New Product Portfolio Delivers Strong Quarterly Performance 14Shire's New Product Portfolio Delivers Strong Quarterly Performance 15Shire's New Product Portfolio Delivers Strong Quarterly Performance 16Shire's New Product Portfolio Delivers Strong Quarterly Performance 17Shire's New Product Portfolio Delivers Strong Quarterly Performance 18Shire's New Product Portfolio Delivers Strong Quarterly Performance 19Shire's New Product Portfolio Delivers Strong Quarterly Performance 20Shire's New Product Portfolio Delivers Strong Quarterly Performance 21Shire's New Product Portfolio Delivers Strong Quarterly Performance 22Shire's New Product Portfolio Delivers Strong Quarterly Performance 23Shire's New Product Portfolio Delivers Strong Quarterly Performance 24Shire's New Product Portfolio Delivers Strong Quarterly Performance 25Shire's New Product Portfolio Delivers Strong Quarterly Performance 26Shire's New Product Portfolio Delivers Strong Quarterly Performance 27Shire's New Product Portfolio Delivers Strong Quarterly Performance 28Shire's New Product Portfolio Delivers Strong Quarterly Performance 29
    (Date:10/22/2014)... Inc. (NASDAQ: AWRE ), a leading supplier of ... third quarter ended September 30, 2014. Revenue for ... of 40% compared to $4.3 million in the same quarter ... was $4.1 million compared to $1.0 million in the third ... month period was primarily due to: i) a $1.0 million ...
    (Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
    (Date:10/17/2014)... This news release is available in German . ... need millions of sperms every day in order to reproduce? ... questions are the topic of the latest issue of the ... 16th, 2014). The evolutionary biologist Steven Ramm from Bielefeld University ... nature, it is not unusual for a female to copulate ...
    Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2
    ... cultivation has expanded dramatically in recent decades and is ... This is because oil palm is grown in lowland ... terrestrial habitats: tropical rainforests. Analysis of the published literature ... Museum of Zoology, Cambridge has revealed significant changes in ...
    ... rivers transport huge quantities of dissolved organic carbon (DOC) ... in arctic rivers is that it is largely ... of the Arctic Ocean. However, a recent study by ... and colleagues at collaborating institutions challenges that assumption by ...
    ... The U.S. Department of Homeland,Security (DHS) announced ... from international visitors arriving at San Francisco,International ... of the,department,s upgrade from two- to 10-fingerprint ... by more accurately and,efficiently establishing and verifying ...
    Cached Biology News:Scientists expand understanding of how river carbon impacts the Arctic Ocean 2DHS Begins Collecting 10 Fingerprints From International Visitors at San Francisco International Airport 2
    ... Trap is specifically designed for efficient ... as DMSO and DMF in the ... refrigeration system set at -5 o ... DMSO, while completely eliminating the risk ...
    Thermo Forma provides an array of accessory Racks for the Cryo/CryoPlus 16" Diameter storage system. To maximise inventory capacity a Jumbo Arrowhead configuration is recommended. You may choose betw...
    ... combine high durability and capacity with unequalled ... mechanism prevents vibration, allowing the unit to ... other part, from the large rubber block ... aluminum platform is designed to last through ...
    The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
    Biology Products: